Mechanistic computational modeling of monospecific and bispecific antibodies targeting interleukin-6/8 receptors
Christina M. P. Ray,Huilin Yang,Jamie B. Spangler,Feilim Mac Gabhann
DOI: https://doi.org/10.1371/journal.pcbi.1012157
2024-06-08
PLoS Computational Biology
Abstract:The spread of cancer from organ to organ (metastasis) is responsible for the vast majority of cancer deaths; however, most current anti-cancer drugs are designed to arrest or reverse tumor growth without directly addressing disease spread. It was recently discovered that tumor cell-secreted interleukin-6 (IL-6) and interleukin-8 (IL-8) synergize to enhance cancer metastasis in a cell-density dependent manner, and blockade of the IL-6 and IL-8 receptors (IL-6R and IL-8R) with a novel bispecific antibody, BS1, significantly reduced metastatic burden in multiple preclinical mouse models of cancer. Bispecific antibodies (BsAbs), which combine two different antigen-binding sites into one molecule, are a promising modality for drug development due to their enhanced avidity and dual targeting effects. However, while BsAbs have tremendous therapeutic potential, elucidating the mechanisms underlying their binding and inhibition will be critical for maximizing the efficacy of new BsAb treatments. Here, we describe a quantitative, computational model of the BS1 BsAb, exhibiting how modeling multivalent binding provides key insights into antibody affinity and avidity effects and can guide therapeutic design. We present detailed simulations of the monovalent and bivalent binding interactions between different antibody constructs and the IL-6 and IL-8 receptors to establish how antibody properties and system conditions impact the formation of binary (antibody-receptor) and ternary (receptor-antibody-receptor) complexes. Model results demonstrate how the balance of these complex types drives receptor inhibition, providing important and generalizable predictions for effective therapeutic design. Metastasis, the process of cancer cells spreading from one organ to another, leads to more severe disease and poorer outcomes for patients; unfortunately, many current drugs focus solely on halting tumor growth rather than directly addressing the spread of cancer cells. Two proteins that regulate the immune system, interleukin-6 and interleukin-8, work together to promote cancer spread when secreted by metastatic cancer cells. By blocking the receptors for these proteins, we can reduce cancer cell migration. Bispecific antibodies are an attractive therapeutic format because they can bind to two different targets at the same time, making them potentially more targeted (cell-type specific) and thus more effective than traditional monospecific antibodies. Here, we built a computational model of a novel bispecific antibody, BS1, that can bind to both an interleukin-6 receptor and an interleukin-8 receptor, and thus targets the interleukin-6/interleukin-8 system for the prevention of metastasis. We compare our model simulations of BS1 to simulations of antibodies that bind only one receptor, and thereby demonstrate how the bispecific characteristic of antibodies affects target inhibition. This provides important insights into the optimal design for BS1 and other bispecific therapeutics.
biochemical research methods,mathematical & computational biology